TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02275104

Intervention type: DEVICE
Intervention: Contrast-enhanced ECG-gated multi-detector computed tomography
Description: Depending on potential contra-indications to iodine-enhanced computed tomography. It will be performed using the usual method on a 64-slice dual energy scanner. Data will be acquired after the injection of 120 mL iodine contrast media. Contrast will be injected at the rate of 4 mL/s without additional saline flush in order to obtain homogeneous enhancement of the 4 cardiac chambers, there by simplifying subsequent segmentation. The objective will be to obtain a 3-dimensional imaging of cardiac structures
Study: NCT02801747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart to Heart2 (HTH2)
Description: The present study uses a fractional factorial design to evaluate the efficacy of five distinct culturally appropriate intervention components on the primary outcome, HIV viral suppression.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart to Heart2 (HTH2)
Description: The present study uses a fractional factorial design to evaluate the efficacy of five distinct culturally appropriate intervention components on the primary outcome, HIV viral suppression.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart to Heart2 (HTH2)
Description: The present study uses a fractional factorial design to evaluate the efficacy of five distinct culturally appropriate intervention components on the primary outcome, HIV viral suppression.
Study: NCT03867383

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 60 milliliters normal saline
Study: NCT02210884

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: Weekly oral supplementation with 15,000 IU vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Weekly oral supplementation with 15,000 IU vitamin D
Study: NCT00387712

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Velocity based treadmill training
Description: 6 month of progressive treadmill walking with a safety harness and hand rail support to prevent falls. Treadmill speed is gradually progressed to meet the training heart rate goals for moderate aerobic exercise, when hemiparetic gait velocity can no longer be progressed, incline is added to achieve heart rate training goals. Progression is also based on participant's tolerance, abilities and safety.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Duration based treadmill training
Description: 6 month of progressive treadmill walking with a safety harness and hand rail support to prevent falls. Treadmill duration is gradually progressed to meet the endurance goals for low aerobic intensity exercise, gait velocity and incline do not progress. Progression is based on participant's tolerance, abilities and safety.
Study: NCT01121068

Intervention type: OTHER
Intervention: Blood samplings
Description: About 3.5ml of blood will be drawn from the participants monthly.
Study: NCT02763800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: BIA 3-202 (50, 100 and 200 mg) was administered in the form of oral tablets, given with 200 ml potable water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: BIA 3-202 (50, 100 and 200 mg) was administered in the form of oral tablets, given with 200 ml potable water.
Study: NCT02384681

Intervention type: OTHER
Intervention: Exposure to auditory fatigue
Description: 12-hour auditory exposure
Study: NCT04083014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination of a single dose anti-CD20 antibody and bortezomib
Description: Relapsed and refractory warm AIHA patients receive treatment of combination of a single dose anti-CD20 antibody and bortezomib twice during three months interval.
Study: NCT03496454

Intervention type: OTHER
Group type: OTHER
Intervention: PfSPZ Challenge
Description: The administration of an injection PfSPZ Challenge in Gambian adults
Study: NCT01626859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-214 3mg
Description: Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for twelve weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-214 6mg
Description: Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for twelve weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-214 9mg
Description: Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for twelve weeks.
Study: NCT01653197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: No scratch off element
Study: NCT02763800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: BIA 3-202 (50, 100 and 200 mg) was administered in the form of oral tablets, given with 200 ml potable water.
Study: NCT02763800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: BIA 3-202 (50, 100 and 200 mg) was administered in the form of oral tablets, given with 200 ml potable water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo was administered in the form of oral tablets, given with 200 ml potable water
Study: NCT04406181

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HADS
Description: Hospital Anxiety and Depression Scale

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: a survey
Description: made up specifically for issues concerning the medical/psychological/access aspects during the COVID-19 outbreak

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: a survey
Description: made up specifically for issues concerning the medical/psychological/access aspects during the COVID-19 outbreak

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: a survey
Description: made up specifically for issues concerning the medical/psychological/access aspects during the COVID-19 outbreak
Study: NCT02607774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: midazolam administered to all patients Days -7, 1 and 35.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: secukinumab administered at Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24
Study: NCT02976558

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clown theatrical Performance

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture according to Traditional Chinese Medicine

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy TaKeTiNa
Study: NCT00887315

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel and cisplatin
Description: Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 IV repeated every 21 days for 2 additional cycles. For patients randomized to group 1, the chemotherapy is identical to that administered for the first 2 cycles

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel and cisplatin Plus Hypofractionated Radiotherapy
Description: Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 IV for 2 cycles along with hypofractionated radiotherapy to all known sites of disease
Study: NCT03732482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide capsules
Description: Temozolomide capsules(Jiangsu tasly diyi pharmaceutical Co.,Ltd) Oral Temozolomide capsules 75mg/m2 begins on day 1 and continues until completion of radiotherapy.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: radiotherapy
Description: Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost
Study: NCT04830371

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EuTCV (Vi-CRM Typhoid conjugate vaccine)
Description: Single dose, Intramuscular administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EuTCV (Vi-CRM Typhoid conjugate vaccine)
Description: Single dose, Intramuscular administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EuTCV (Vi-CRM Typhoid conjugate vaccine)
Description: Single dose, Intramuscular administration

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Typbar-TCV
Description: Single dose, Intramuscular administration
Study: NCT01800929

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: N6
Description: Children with N5 will be upgraded to the N6 for a period of up to 2 months to evaluate.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: N6
Description: Children with N5 will be upgraded to the N6 for a period of up to 2 months to evaluate.
Study: NCT02605343

Intervention type: OTHER
Intervention: NeuroIDgenetix Test Panel
Description: The NeuroIDgenetix Test Panel is used to make recommendations on post-operative pain medication therapy that may be impacted by the genetic background of the patient.
Study: NCT04028804

Intervention type: PROCEDURE
Intervention: FDG PET
Description: Each patient will receive a single intravenous injection of FDG (5.18 MBq/kg (0.14 mCi/kg)) using a minimum dose of 37 MBq (1 mCi) up to a maximum of 370 MBq (10 mCi) with an accepted 10%-20% variation since dose variation can occur when small concentrated volumes of FDG are being drawn up or radioactive decay has reduced the amount of available.

Intervention type: PROCEDURE
Intervention: FDG PET
Description: Each patient will receive a single intravenous injection of FDG (5.18 MBq/kg (0.14 mCi/kg)) using a minimum dose of 37 MBq (1 mCi) up to a maximum of 370 MBq (10 mCi) with an accepted 10%-20% variation since dose variation can occur when small concentrated volumes of FDG are being drawn up or radioactive decay has reduced the amount of available.

Intervention type: PROCEDURE
Intervention: FLT PET
Description: The FLT PET scan will be performed 1-5 days after FDG PET in order to ensure consistency between imaging findings. Each patient will receive a single intravenous injection of FLT (5.18 MBq/kg (0.14 mCi/kg)) using a minimum dose of 37 MBq (1 mCi) up to a maximum of 370 MBq (10 mCi) with an accepted 10%-20% variation since dose variation can occur when small concentrated volumes of FLT are being drawn up or radioactive decay has reduced the amount of available.

Intervention type: PROCEDURE
Intervention: FLT PET
Description: The FLT PET scan will be performed 1-5 days after FDG PET in order to ensure consistency between imaging findings. Each patient will receive a single intravenous injection of FLT (5.18 MBq/kg (0.14 mCi/kg)) using a minimum dose of 37 MBq (1 mCi) up to a maximum of 370 MBq (10 mCi) with an accepted 10%-20% variation since dose variation can occur when small concentrated volumes of FLT are being drawn up or radioactive decay has reduced the amount of available.
Study: NCT03231995

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collection of nasopharyngeal specimen collected at D0, D1, D2 and D5.
Description: Analyses will be performed on nasopharyngeal specimen collected at D0, D1, D2 and D5.~Definition and validation of nasopharyngeal microbiome biomarkers (bacterial, viral, transcriptomic signature)
Study: NCT02656004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Essential Eucalyptus Oil
Description: Using a disposable face mask was inhale for ten minutes 0.25 ml of essential oil of eucalyptus measured through adjustable Pipettor 100/1000μl. Inhalation of the substance occurred immediately after the 20 minute rest period in the session Essential Oil of Eucalyptus.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Session
Description: In the control session the procedure was the same. Using a disposable face mask was inhale for ten minutes fresh air. Inhalation of the fresh air occurred immediately after the 20 minute rest period in the session Control.
Study: NCT02390596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: The dose of Anakinra will be 2mg/kg (patients \<10kg and/or \<8 months: 4mg/kg). If the patient remains febrile (fever \>38°C), he will receive a double dose of anakinra 4mg/kg (patients \<10kg and/or \<8 months: 6mg/kg) at day1 instead of 2mg/kg. If the patient does not respond to the 4mg/kg dose at visit 3; d1 within 24 hours, he will receive at visit 4; d2, 6mg/kg of anakinra (patients \<10kg and/or \<8 months: 8mg/kg). Treatment will be continued until they have achieved complete response as defined in the outcome measurement section, and during a maximum of 15 days.
Study: NCT02527746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-627
Description: F-627 subcutaneous injection on Day 3 of each cycle for 4 cycles. Dose-escalation method was used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-627
Description: F-627 subcutaneous injection on Day 3 of each cycle for 4 cycles. Dose-escalation method was used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-627
Description: F-627 subcutaneous injection on Day 3 of each cycle for 4 cycles. Dose-escalation method was used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC regimen
Description: Epirubicin 100 mg/m\^2 (in vein) and Cyclophosphamide 600 mg/m\^2 (in vein) on Day 1 of each cycle for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC regimen
Description: Epirubicin 100 mg/m\^2 (in vein) and Cyclophosphamide 600 mg/m\^2 (in vein) on Day 1 of each cycle for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC regimen
Description: Epirubicin 100 mg/m\^2 (in vein) and Cyclophosphamide 600 mg/m\^2 (in vein) on Day 1 of each cycle for 4 cycles.
Study: NCT01583309

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: online pre-dilution hemofiltration
Description: Online pre-dilution hemofiltration was performed with a synthetic high-flux membrane and an infusate/blood flow ratio of one

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: online pre-dilution hemodiafiltration
Description: Online pre-dilution hemodiafiltration was performed with a synthetic high-flux membrane with an infusate/blood flow ratio of 0.6 and a dialysate plus infusate rate of 700 ml/min.
Study: NCT03892044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT00481351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 20mg plus ezetimibe 10mg
Description: simvastatin 20mg plus ezetimibe 10mg once a day for 6 week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe
Description: ezetimiba 10mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin 20mg
Description: simvastatin 20mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 80mg
Description: simvastatin 20mg for 6week and then simvastatin 80mg for the next 6week.
Study: NCT05230706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cephalic helmet
Description: An acrylic headgear (length: 27 cm; width: 27 cm; height: 17.5 cm; opening: 17x12 cm) was placed on the patient's head. The helmet was covered with surgical cloth (green or blue) folded into 50x60cm rectangles, leaving the front part open to maintain adequate airflow.
Study: NCT03937895

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 'SMT-NK' Inj (allogeneic Natural Killer cell)
Description: In 120 mL, 3x10\^6 (± 20%) cells/kg. weekly administration via Intravenous for 2 weeks. After that, 1 week is a withdrawal period.
Study: NCT02763800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo was administered in the form of oral tablets, given with 200 ml potable water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo was administered in the form of oral tablets, given with 200 ml potable water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo was administered in the form of oral tablets, given with 200 ml potable water
Study: NCT01403896

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plerixafor (Mozobil)
Description: They will receive Plerixafor (240 µg/kg/day subcutaneously for 1 dose) on Day 0 at 8 am

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor + G-CSF
Description: They will receive G-CSF (5 µg/kg/day) for 4 days (Days -4,-3,-2,-1 at 8 am) followed by Plerixafor (240 µg/kg/day subcutaneously for 1 dose) on Day 0 at 8 am
Study: NCT00384904

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Atazanavir/Ritonavir
Description: Capsules/capsules, Oral, 300/100 mg, Once daily, 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/Ritonavir + Famotidine
Description: Capsules/capsules + Tablets, Oral, 300/100 mg + 40 mg, Once daily + Twice daily, 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/Ritonavir + Famotidine
Description: Capsules/capsules + Tablets, Oral, 300/100 mg + 20 mg, Once daily + Twice daily, 7 days.
Study: NCT03937895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection [Keytruda]
Description: Administration via Intravenous of 200 mg every 3 weeks(one administration per cycle.).
Study: NCT00101166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bystander-Based Autologous Tumor Cell Vaccine
Description: The vaccine, consisting of one mL of cell suspension (GM.CD40L bystander cells admixed with an equivalent number of thawed autologous tumor cells), was administered into 8 separate injection sites, as described in treatment arm.
Study: NCT00384904

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Atazanavir/Ritonavir
Description: Capsules/capsules + Tablets, Oral, 300/100 mg, Once daily, 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine
Description: Capsules/capsules + Tablets + Tablets, Oral, 300/100 mg + 300 mg + 40 mg, Once daily + Twice daily, 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine
Description: Capsules/capsules + Tablets + Tablets, Oral, 300/100 mg + 300 mg + 20 mg, Once daily + Twice daily, 7 days.
Study: NCT02877875

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems
Description: MATCH-ADTC (Chorpita \& Weisz, 2009) is designed for children aged 6-15. Unlike most evidence-based treatments (EBTs), which focus on single disorder categories (e.g., anxiety only), MATCH is designed for multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with Attention-deficit/hyperactivity disorder (ADHD). MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring and Feedback System
Description: For each child, the web-based MFS system provides weekly monitoring of the MATCH modules used and the child's treatment response, in two forms (a) changes on the Behavior and Feelings Survey and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, the MFS provides a complete record of modules used, and child treatment response, across all the weeks of treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment in the UC condition will use the procedures therapists (e.g., school counselors) and their supervisors consider appropriate and believe to be effective.
Study: NCT03652220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation Based Lifestyle Modification
Description: 8 weekly modules, each 3.5 hours of Life ethics, Yoga exercises and Mantra Meditation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Minimal treatment
Description: Drug continuation under medical supervision

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal specific treatment:
Description: Drugs / Psychotherapy / Excercise therapy / Ergotherapy / Relaxation; excl. Yoga, Mantra, MBSR

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal specific treatment:
Description: Drugs / Psychotherapy / Excercise therapy / Ergotherapy / Relaxation; excl. Yoga, Mantra, MBSR
Study: NCT01311076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-329
Description: TAK-329 50 mg, tablets, orally, single dose, one day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-329
Description: TAK-329 200 mg, tablets, orally, single dose, one day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin 0.2 U/kg, subcutaneous injection, single dose, one day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-329 placebo-matching tablets, orally, single dose, one day.
Study: NCT02439814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone
Description: Pregnenolone is a steroid that occurs naturally in the body, and early studies have shown that pregnenolone may block the effects of marijuana intoxication

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive comparator
Study: NCT02183038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam high

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen sodium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam placebo low

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meloxicam placebo low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam placebo high

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meloxicam placebo high

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium placebo
Study: NCT02975388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7079901
Description: Participants will receive a single dose of 1000 milligrams (mg) RO7079901 as a 30-minute intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7079901
Description: Participants will receive a single dose of 1000 milligrams (mg) RO7079901 as a 30-minute intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7079901
Description: Participants will receive a single dose of 1000 milligrams (mg) RO7079901 as a 30-minute intravenous (IV) infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RO7079901
Description: Participants will receive a single dose of 1000 milligrams (mg) RO7079901 as a 30-minute intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7079901
Description: Participants will receive a single dose of 1000 milligrams (mg) RO7079901 as a 30-minute intravenous (IV) infusion.